SI0781778T1 - Paklitakselna predzdravila, metoda za pripravo in njihova uporaba pri selektivni kemoterapiji - Google Patents
Paklitakselna predzdravila, metoda za pripravo in njihova uporaba pri selektivni kemoterapijiInfo
- Publication number
- SI0781778T1 SI0781778T1 SI9630480T SI9630480T SI0781778T1 SI 0781778 T1 SI0781778 T1 SI 0781778T1 SI 9630480 T SI9630480 T SI 9630480T SI 9630480 T SI9630480 T SI 9630480T SI 0781778 T1 SI0781778 T1 SI 0781778T1
- Authority
- SI
- Slovenia
- Prior art keywords
- paclitaxel
- beta
- prodrugs
- prodrug
- preparation
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C263/00—Preparation of derivatives of isocyanic acid
- C07C263/12—Preparation of derivatives of isocyanic acid from or via nitrogen analogues of carboxylic acids, e.g. from hydroxamic acids, involving a Hofmann, Curtius or Lossen-type rearrangement
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95203671 | 1995-12-29 | ||
EP96203571A EP0781778B1 (en) | 1995-12-29 | 1996-12-17 | Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SI0781778T1 true SI0781778T1 (sl) | 2002-10-31 |
Family
ID=8221031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9630480T SI0781778T1 (sl) | 1995-12-29 | 1996-12-17 | Paklitakselna predzdravila, metoda za pripravo in njihova uporaba pri selektivni kemoterapiji |
Country Status (10)
Country | Link |
---|---|
US (1) | US5760072A (sl) |
EP (1) | EP0781778B1 (sl) |
JP (1) | JPH09202796A (sl) |
AT (1) | ATE216394T1 (sl) |
CA (1) | CA2192424C (sl) |
DE (1) | DE69620727T2 (sl) |
DK (1) | DK0781778T3 (sl) |
ES (1) | ES2175028T3 (sl) |
PT (1) | PT781778E (sl) |
SI (1) | SI0781778T1 (sl) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE310538T1 (de) * | 1996-04-15 | 2005-12-15 | Asahi Chemical Ind | Arzneimittelkomplexe enthaltend taxan- verbindungen oder steroiden |
US7357942B2 (en) * | 1997-09-26 | 2008-04-15 | Abbott Laboratories | Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens |
WO1999018113A1 (fr) * | 1997-10-08 | 1999-04-15 | Bio Research Corporation Of Yokohama | Derives taxoides et leur procede de production |
US5981564A (en) * | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
DE19845798A1 (de) * | 1998-09-29 | 2000-04-13 | Schering Ag | Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung |
US6043367A (en) * | 1998-09-30 | 2000-03-28 | Roffler; Steve | Proactive antitumor compounds |
US20050222246A1 (en) * | 1999-04-14 | 2005-10-06 | Li Chiang J | Beta-lapachone is a broad spectrum anti-cancer agent |
US20050192360A1 (en) * | 1999-04-14 | 2005-09-01 | Li Chiang J. | Method of treatment of pancreatic cancer |
CA2410632A1 (en) | 2000-06-22 | 2001-12-27 | David S. Garvey | Nitrosated and nitrosylated taxanes, compositions and methods of use |
US20050197405A1 (en) * | 2000-11-07 | 2005-09-08 | Li Chiang J. | Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent |
US7070797B2 (en) * | 2000-11-07 | 2006-07-04 | Dana Farber Cancer Institute, Inc. | Method of treating hematologic tumors and cancers |
MXPA03011094A (es) * | 2001-05-31 | 2004-12-06 | Medarex Inc | Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello. |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
US6816571B2 (en) * | 2002-02-06 | 2004-11-09 | L-3 Communications Security And Detection Systems Corporation Delaware | Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner |
WO2003073988A2 (en) | 2002-02-28 | 2003-09-12 | A & D Bioscience, Inc. | Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof |
WO2003079980A2 (en) * | 2002-03-19 | 2003-10-02 | A & D Bioscience, Inc. | Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof |
US20050255038A1 (en) * | 2002-04-12 | 2005-11-17 | A And D Bioscience, Inc. | Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof |
US20050153928A1 (en) * | 2002-05-07 | 2005-07-14 | Holick Michael F. | Conjugates comprising a central nervous system-active drug linked to glucuronic acid or glucosamine through an amide bond and uses thereof |
NZ537686A (en) * | 2002-06-20 | 2007-01-26 | Nippon Suisan Kaisha Ltd | A beta2 agonist prodrug having reduced side effects |
US20050215487A1 (en) * | 2002-06-27 | 2005-09-29 | Holick Michael F | Conjugates comprising an nsaid and a sugar and uses thereof |
US20050187288A1 (en) * | 2004-02-20 | 2005-08-25 | Chiang Li | Beta-lapachone and methods of treating cancer |
US20050192247A1 (en) * | 2004-02-23 | 2005-09-01 | Li Chiang J. | Method of treating cancers |
US20080312162A1 (en) * | 2004-10-08 | 2008-12-18 | The Ohio State University | Methods and Compositions for Enzyme-Specific Activation of Carbohydrate-Conjugated Prodrugs |
FR2947455B1 (fr) | 2009-07-01 | 2014-01-03 | Centre Nat Rech Scient | La dermaseptine b2 comme inhibiteur de la croissance tumorale |
CN113952464B (zh) * | 2018-03-06 | 2024-10-15 | 江苏吉贝尔药业股份有限公司 | 含酮羰基的疏水性抗肿瘤药物及其应用 |
WO2020044252A1 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Dosage regimes for anti-m-csf antibodies and uses thereof |
US20230293432A1 (en) * | 2020-07-06 | 2023-09-21 | Rheinisch-Westfälische Technische Hochschule (Rwth) | Polymeric micelles comprising glucuronide-prodrugs |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
-
1996
- 1996-09-30 US US08/722,941 patent/US5760072A/en not_active Expired - Fee Related
- 1996-12-09 CA CA002192424A patent/CA2192424C/en not_active Expired - Fee Related
- 1996-12-17 EP EP96203571A patent/EP0781778B1/en not_active Expired - Lifetime
- 1996-12-17 DK DK96203571T patent/DK0781778T3/da active
- 1996-12-17 DE DE69620727T patent/DE69620727T2/de not_active Expired - Fee Related
- 1996-12-17 ES ES96203571T patent/ES2175028T3/es not_active Expired - Lifetime
- 1996-12-17 AT AT96203571T patent/ATE216394T1/de not_active IP Right Cessation
- 1996-12-17 PT PT96203571T patent/PT781778E/pt unknown
- 1996-12-17 SI SI9630480T patent/SI0781778T1/sl unknown
- 1996-12-27 JP JP8351525A patent/JPH09202796A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JPH09202796A (ja) | 1997-08-05 |
DE69620727D1 (de) | 2002-05-23 |
CA2192424C (en) | 2002-01-22 |
ATE216394T1 (de) | 2002-05-15 |
DK0781778T3 (da) | 2002-06-17 |
PT781778E (pt) | 2002-08-30 |
US5760072A (en) | 1998-06-02 |
ES2175028T3 (es) | 2002-11-16 |
EP0781778A1 (en) | 1997-07-02 |
EP0781778B1 (en) | 2002-04-17 |
CA2192424A1 (en) | 1997-06-30 |
DE69620727T2 (de) | 2002-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI0781778T1 (sl) | Paklitakselna predzdravila, metoda za pripravo in njihova uporaba pri selektivni kemoterapiji | |
AU735243B2 (en) | Peptidyl prodrugs and methods of making and using the same | |
CA2336815A1 (en) | Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides | |
WO2002007759A3 (en) | Clostridial toxin derivatives and methods for treating pain | |
IL133585A0 (en) | Soluble prodrugs of paclitaxel | |
PT1183050E (pt) | Processo para a produção de uma preparação farmacêutica injectável | |
CA2455774A1 (en) | Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain | |
WO1998000172A3 (en) | Compositions and methods for altering the biodistribution of biological agents | |
WO1988000837A3 (en) | Advanced anticancer therapy and cytotoxic medicaments for its implementation | |
UA41446C2 (uk) | Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі | |
PT740650E (pt) | Co-farmacos como um metodo de administracao controlada de farmacos | |
CA2211118A1 (en) | Stable lipid-comprising drug delivery complexes and methods for their production | |
CA2258548A1 (en) | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases | |
CA2282082A1 (fr) | Microgranules contenant du cisplatine | |
WO2000001376A3 (en) | Pharmaceutical compositions and their uses for treatment of demyelinating disorders | |
AU1313095A (en) | Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbb plays a role | |
DE69533615D1 (de) | Anthracyclin Prodrugs, Verfahren zu deren Herstellung und deren Verwendung in der selektiven Chemotherapie | |
WO2001092273A3 (en) | Benzenedicarboxylic acid derivatives | |
WO2005025512A3 (en) | Cobalamin conjugates for anti-tumor therapy | |
WO2003100031A3 (en) | Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues | |
WO1999033450A3 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
CA2356959A1 (en) | Water-insoluble drug delivery system | |
CA2083377A1 (en) | Compositions and methods for modulating rna activity through modification of the 5' cap structure of rna | |
WO2004058143A3 (en) | High specificity anticancer pharmacological drug system, drug synthesis, and drug development process | |
AU5819296A (en) | Pharmaceutical composition prepared by addition of a flavour vehicle to a medicament |